Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, and Day Zero Diagnostics (DZD)
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.